Target IGF-1 Levels for Patients on Norditropin Therapy

Age and Developmental Stage Considerations

• The Endocrine Society recommends that IGF-1 levels in patients receiving Norditropin should be maintained within the age-adjusted, sex-adjusted, and Tanner stage-matched normal reference range, typically targeting the mid-to-upper portion of the normal range (approximately 0 to +2 SDS) to optimize therapeutic efficacy while minimizing adverse effects 1, 2, 3
• Tanner stage-matched reference ranges are essential for accurate interpretation, as IGF-1 levels naturally peak during mid-puberty (Tanner stages 2-3) 1, 2
• Inter-assay variability is substantial, requiring use of laboratory-specific reference ranges for the specific IGF-1 assay being utilized 1, 2, 4

Monitoring Strategy

• The standard dosing is 0.045-0.05 mg/kg/day administered as daily subcutaneous injections 5
• Baseline assessment before initiating therapy should establish age-matched, sex-matched, and (in children) Tanner stage-matched reference ranges specific to the laboratory's assay 1, 2, 4

Critical Confounding Factors That Alter IGF-1 Interpretation

• Severe hypothyroidism suppresses hepatic IGF-1 generation 1, 2, 6
• Malnutrition or energy deficiency directly suppresses IGF-1 production 1, 2, 6
• Oral estrogen therapy reduces hepatic IGF-1 synthesis 1, 2, 6
• Severe infection suppresses the GH-IGF-1 axis 1, 2, 6
• Poorly controlled diabetes mellitus can produce spuriously elevated IGF-1 levels 1, 2, 4
• Hepatic or renal failure may cause falsely elevated IGF-1 measurements 1, 2, 4

Common Pitfalls to Avoid

• Do not use a single universal IGF-1 cutoff across all ages, as IGF-1 physiologically declines substantially with aging 4, 6
• Do not assume all elevated IGF-1 values indicate overdosing, as in adolescents during peak growth spurts, mild elevations may be physiologically appropriate 1, 2
• Do not compare IGF-1 values across different laboratory assays without understanding assay-specific reference ranges, as inter-assay variability is substantial 1, 2, 4

Dose Adjustment Algorithm

• If IGF-1 is below the age-adjusted reference range despite adequate dosing, evaluate for confounding factors (hypothyroidism, malnutrition, oral estrogens) before increasing dose 1, 2, 6